Eli Lilly's oral GLP-1 drug orforglipron demonstrates significant cardiovascular safety and efficacy in phase 3 trials, showing a 16% lower risk of MACE-4 and a 53% reduction in cardiovascular death.
Lilly's oral GLP-1 orforglipron demonstrated cardiovascular safety and efficacy in a large phase 3 trial, strengthening its diabetes portfolio and competitive position.
Eli Lilly's oral GLP-1 candidate, orforglipron, met primary non-inferiority objectives in the ACHIEVE-4 phase 3 trial. Data revealed a 16% reduction in MACE-4 risk and a 53% lower risk of cardiovascular death compared to insulin glargine, bolstering the company's diabetes treatment portfolio.
The trial confirms the cardiovascular safety and efficacy of orforglipron, supporting its potential as a key oral treatment option in Lilly's diabetes portfolio.